RESEARCH MONOGRAPH · KDC-MN-358

ACE-031

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

66/100

Activin receptor trap that produced striking lean mass gains and then ran into safety signals in trials

ACE-031 is one of the more interesting myostatin pathway interventions of the last 15 years, and the trial history tells you both why the pathway is real and why developing drugs in it is hard.

Mechanistically, ACE-031 is a soluble form of the activin receptor type IIB (ActRIIB) extracellular domain fused to an IgG Fc. The trap binds circulating myostatin (GDF-8) plus other ActRIIB ligands including activin A, GDF-11, and BMP-9, sequestering them away from the receptor. Because myostatin is the dominant brake on skeletal muscle hypertrophy, sequestering it produces dose-dependent muscle mass gains. The early phase 1 data in healthy postmenopausal women (Attie group at Acceleron, 2013) showed clear increases in lean mass and thigh muscle volume with single-dose subcutaneous administration. The signal was unambiguous.

The Duchenne muscular dystrophy trials are where development hit trouble. The phase 2 work in DMD boys showed muscle mass gains but also produced signs of nosebleeds and gum bleeding in some participants, which got attributed to the broad ligand sequestration profile (BMP and activin involvement in vascular biology). Acceleron paused the program in 2013 and never restarted it. The story since has been about whether more selective myostatin-only targeting (ApitBatRumab, anti-myostatin antibodies, follistatin analogs) can capture the benefits without the off-target effects.

What we find intriguing from a research angle is what ACE-031 demonstrated about the size of the achievable muscle mass effect in humans. The magnitude of lean mass gain in healthy subjects after a single dose was striking and reproducible, and the fact that the pathway translates so cleanly from mouse models to humans is one of the more satisfying validations in translational myology.

Sourcing as a research reagent is limited. ACE-031 is a recombinant fusion protein, the original Acceleron material isn't broadly available, and most current research-grade equivalents are either internally made or sourced from specialized vendors. QC variability is real, and authentication is essential.

What we dont love is the way the early phase 1 results got picked up in the performance enhancement community without the trial-stopping safety data context. The pathway is real, the magnitude is real, the off-target liabilities are also real.

As a research tool, ACE-031 remains useful for ActRIIB ligand-sequestration studies in muscle and bone biology.

Evidence: 60
Mechanism: 88
Reliability: 75
Safety: 50
Sourcing: 55
Value: 60
Signal: 78
Staying power: 60

Plain-language summary Intrigue 60 / 100

ACE-031 is a soluble decoy receptor designed to soak up myostatin (the molecular brake on muscle growth) and related TGF-beta family ligands before they can engage real receptors on muscle. Built as a fusion of the activin receptor type IIB extracellular domain with an antibody Fc tail for half-life extension, it was developed at Acceleron Pharma for muscular dystrophy. Phase 1 and 2 trials demonstrated meaningful muscle mass increases but were halted in 2013 because of safety signals (epistaxis and gum bleeding, suggesting off-target effects on related TGF-beta ligands involved in vascular biology). The myostatin-trap concept lives on in related compounds. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Activin receptor type IIB ligand trap (myostatin pathway)

A soluble activin receptor type IIB Fc fusion protein that traps myostatin and related ligands; investigated for muscular dystrophy.

Abstract

ACE-031 (sotatercept-related molecule; recombinant Fc fusion of the extracellular domain of human activin receptor type IIB; molecular weight approximately 100 kDa) is a soluble activin receptor type IIB ligand trap developed at Acceleron Pharma. The compound binds and sequesters myostatin (GDF-8), activin A, GDF-11, and other TGF-beta superfamily ligands in plasma, preventing receptor engagement at muscle and other tissues. Mechanism: myostatin pathway inhibition increases muscle mass and strength in preclinical models; the broader ligand trap mechanism distinguishes ACE-031 from antibody-based pure myostatin inhibitors (which target only myostatin). Phase 2 trials in Duchenne muscular dystrophy were halted in 2011 owing to epistaxis and gum bleeding (consistent with broader TGF-beta family disruption affecting vascular biology). The related compound sotatercept (luspatercept's predecessor) was approved for pulmonary arterial hypertension in 2024 with the same scaffold but different ligand binding profile. Used as a research probe for myostatin and broader TGF-beta family pharmacology.

Mechanism of action

Soluble activin receptor type IIB Fc fusion ligand trap; binds and sequesters myostatin, activin A, GDF-11. Increases muscle mass via myostatin inhibition.

Reported research dose ranges

Trial doses 0.5 to 3 mg/kg subcutaneous every 2 to 4 weeks.

References

Cadena SM, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010.
Campbell C, et al. Myostatin inhibitors for Duchenne muscular dystrophy: phase 2 trial results. Muscle Nerve 2017.
Souza TA, et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-358

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

ACE-031

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs